Scholtz & Company’s Apyx Medical APYX Stock Holding History

Scholtz & Company’s Portfolio APYX Stock Details APYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.9K	Hold	10,000	–	–	0.02%	48
2026 Q1	$36.9K	Sell	10,000 -10,000	-50%	-$37.4K	0.02%	49
2025 Q4	$70K	Hold	20,000	–	–	0.03%	51
2025 Q3	$42.8K	Hold	20,000	–	–	0.02%	51
2025 Q2	$45K	Hold	20,000	–	–	0.02%	52
2025 Q1	$27.4K	Hold	20,000	–	–	0.01%	51
2024 Q4	$31.6K	Hold	20,000	–	–	0.02%	48
2024 Q3	$24.8K	Hold	20,000	–	–	0.01%	51
2024 Q2	$26.8K	Hold	20,000	–	–	0.01%	50
2024 Q1	$27.2K	Hold	20,000	–	–	0.01%	50
2023 Q4	$52K	Hold	20,000	–	–	0.03%	66
2023 Q3	$64K	Buy	20,000 +5,000	+33%	+$23.3K	0.04%	40
2023 Q2	$75K	Buy	15,000 +5,000	+50%	+$25.3K	0.05%	38
2023 Q1	$29K	Buy	+10,000	New	+$29.2K	0.02%	34

Other funds holding APYX

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SBCM

Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Scholtz & Company's APYX Position: Q2 2026 in Review

Scholtz & Company held its Apyx Medical (APYX) position steady in Q2 2026 at 10,000 shares worth $44.9K. The position accounts for 0.02% of the portfolio, ranked #48.

Scholtz & Company first reported a position in APYX in Q1 2023 and has held it in 14 quarters since. The position peaked at $75K in Q2 2023. 68 funds tracked by Wall St. Rank hold APYX as of Q2 2026.

Scholtz & Company held 10,000 shares of Apyx Medical worth $44.9K as of Q2 2026.
Scholtz & Company left its Apyx Medical share count unchanged in Q2 2026.
Apyx Medical made up 0.02% of Scholtz & Company's portfolio in Q2 2026, its #48 holding.
Scholtz & Company first reported a position in Apyx Medical in Q1 2023 and has held it in 14 quarters since.
Scholtz & Company's Apyx Medical position peaked at $75K in Q2 2023.
68 funds tracked by Wall St. Rank held Apyx Medical as of Q2 2026.

Based on Scholtz & Company's 13F filing for Q2 2026, filed 11 Aug 2026.